Nicotinamide-Adenine Dinucleotide (NADH) in Parkinson's Disease and Alzheimer's Disease
Author(s): Glasnapp Andrew, Schaefer Erin
Issue: Jul/Aug 2000 - Compounding for Hospice and Cancer Patients
View All Articles in Issue
Page(s): 276-279
Download in electronic PDF format for $65
Abstract: Nicotinamide-adenine dinucleotide (NADH) is currently being tested as a promising new therapy in the treatment of Parkinson’s and Alzheimer’s disease. The authors discuss some of these studies, in addition to providing figures showing the synthesis of dopamine and the Kreb’s cycle and providing tables showing results of the Birkmayer Parkinison’s Disease Study and the Mini-Mental State Examination. They also provide a formulation for NADH Capsules.
Related Keywords: adenine, alzheimer's, coenzyme I, dinucleotide, dopamine, levodopa, mini-mental state exam, motor function, NADH, neurochemistry, neurology, Nicotinamide, parkinson's, tetrahydrobiopterin, tyrosine